BCM
RDY icon

BlueCrest Capital Management’s Dr. Reddy's Laboratories RDY Stock Holding History

BlueCrest Capital Management’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-34,505
Closed -$222K – 1749
2018
Q2 		$222K Buy
+34,505
New +$218K 0.01% 1262

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

BlueCrest Capital Management's RDY Position: Q3 2018 in Review

BlueCrest Capital Management sold out of Dr. Reddy's Laboratories (RDY) in Q3 2018, closing a stake of 34,505 shares — an estimated $222K sold.

BlueCrest Capital Management first reported a position in RDY in Q2 2018 and held it in 1 quarter. The position peaked at $222K in Q2 2018. 125 funds tracked by Wall St. Rank hold RDY as of Q3 2018.

  • BlueCrest Capital Management reported no remaining Dr. Reddy's Laboratories position as of Q3 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 34,505 Dr. Reddy's Laboratories shares in Q3 2018, an estimated $222K.
  • BlueCrest Capital Management first reported a position in Dr. Reddy's Laboratories in Q2 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Dr. Reddy's Laboratories position peaked at $222K in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2018.

Based on BlueCrest Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.